Ligand Pharmaceuticals and Spectrum sign global melphalan license agreement Ligand Pharmaceuticals (LGND) signed global license and supply agreements with Spectrum (SPPI) for the development and commercialization of Ligandís Captisol-enabled, propylene glycol-free melphalan. Ligand is entitled to receive a license fee and is eligible to receive more than $50M in potential milestone payments. Ligand is also eligible to receive royalties on future net sales of Captisol-enabled melphalan.
News For LGND;SPPI From The Last 14 Days
Check below for free stories on LGND;SPPI the last two weeks.